Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.57 |
| ▸ | NOS1 | P29475 | 5/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367991 | 0.88 | SIGMAR1 (0.55) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5621292 | 0.82 | NOS1 (0.69) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5621288 | 0.82 | NOS1 (0.69) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14459684 | 0.81 | NOS1 (0.46) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14368025 | 0.79 | SIGMAR1 (0.54) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL17254179 | 0.79 | SIGMAR1 (0.54) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL8397922 | 0.77 | SIGMAR1 (0.64) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14368020 | 0.76 | SIGMAR1 (0.55) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14518685 | 0.74 | SIGMAR1 (0.40) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14368067 | 0.74 | LMNA (0.44) | SIGMAR1NOS1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | SIGMAR1 37/4885NOS1 1323/4885GRIN2D 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.